NOTE

🌱 created from: acute lymphoblastic leukemia

treatment_of_all

• A patient who presents with B-cell ALL requires intensive combination therapy. HyperCVAD + Rituximab (If the patient has ALL that is CD20+) is a common regimen given to adult patients with ALL.
  • Patients with Ph- ALL with CD20 expression have an adverse prognosis.
• The preferred regimen for adult patients <65 years of age and without substantial comorbidities who have Ph- ALL is the ECOG-ACRIN E1910
• The CALGB 8811(Larson regimen)， GRAALL-2005,USC/MSKCC ALL regimen, Linker 4-drug， MRC UKALLXII/ECOG2993, Inotuzumab ozogamicin + mini-hyper-CVD and Blinatumomab are other regimens that one can give. Please see the NCCN guidelines （reference below） to see the various chemotherapeutics contained in these regimens.

INO-VATE ALL